Epigenomics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Epigenomics's estimated annual revenue is currently $10.4M per year.(i)
  • Epigenomics's estimated revenue per employee is $155,000

Employee Data

  • Epigenomics has 67 Employees.(i)
  • Epigenomics grew their employee count by -7% last year.

Epigenomics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CFO / VorstandReveal Email/Phone
3
VP Clinical and Scientifc AffairsReveal Email/Phone
4
EVP FinanceReveal Email/Phone
5
Director, Technical Support & CRAReveal Email/Phone
6
President & Chief Scientific OfficerReveal Email/Phone
7
Director Facilities, Logistics, EH&S San Diego FacilityReveal Email/Phone
8
Area Business ManagerReveal Email/Phone
9
Executive Administrative Assistant & HR ManagerReveal Email/Phone
10
Manufacturing ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Epigenomics?

Epigenomics is a molecular diagnostics company focused on the development of blood-based DNA methylation tests for the early the detection of cancer. The Epi proColon test has recently become the first and only FDA approved blood test for colorectal cancer screening. Epi proColon, HCCBloodTest, and the Epi proLung tests are available in Europe as CE-marked IVDs. Industry partners, as well as the medical and life science communities, can access our expansive intellectual property portfolio. Epigenomics has been granted over 60 patents, in addition to many others that have been filed. These patents cover DNA methylation technologies and biomarkers, as well as our DNA methylation expertise through research products, biomarker services, IVD development collaborations, and licensing.

keywords:N/A

N/A

Total Funding

67

Number of Employees

$10.4M

Revenue (est)

-7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Epigenomics News

2022-04-17 - Global In-Vitro Colorectal Cancer Screening Tests Market ...

Beckman Coulter; Alere; Epigenomics; Eiken Chemical; Sysmex; Siemens Healthcare; Quest Diagnostics; Companion Dx; Oncocyte; Merck Millipore...

2022-04-17 - Cancer Biomarkers Market Upcoming Trends, Future ...

... Upcoming Trends, Future Demands and Forecast by 2030 | Astellas Pharma Inc., Myriad Genetics, Epigenomics, Radient Pharmaceuticals.

2022-03-22 - Epigenomics Posts Strong Revenue Gains in 2021 on Blood ...

NEW YORK — Epigenomics on Thursday posted a sharp year-over-year increase in revenues for 2021, even as sales of its diagnostic test kits fell,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.4M67-9%N/A
#2
$8.5M67-9%N/A
#3
$8.7M6710%N/A
#4
$13.3M67N/AN/A
#5
$10.4M6737%N/A